It has been suggested that EGFR-TKIs or PD-1/PD-L1 inhibitors may also play a therapeutic role in NSCLC through anti-inflammatory and antioxidant mechanisms (Liao et al., 2012). Here, EGFR is linked to non-small cell lung carcinoma.